CD8A and neoplasm: Since CD8+ cytotoxic T lymphocytes (CTLs) are key to tumor cell killing, the results indicate that the in vivo CAP treatment inhibits proliferation of tumor-infiltrating CD8+ CTLs, but has no effect in suppressing migration of T cells out of the spleen.